Vaccine Development and Clinical Trials
Determining that a vaccine will be a safe and effective response to an infectious disease starts with laboratory testing of a scientific concept. It then moves to animal and human testing. This session will explore the development and clinical trial processes, using examples of the COVID-19 vaccines to improve understanding.
- Development
- Clinical Trials
Michael L. Gruver, Senior Corporate Counsel, Pfizer, Inc.
Jonathan Walland, Senior Corporate Counsel, Pfizer, Inc.
This session was recorded as part of FDLI’s Virtual Fundamentals of Vaccine Regulation Course in February 2021.
MICHAEL L. GRUVER is Senior Corporate Counsel in Pfizer’s Clinical Development Legal group. He supports legal issues related to clinical trials in Pfizer’s Vaccine, Rare Disease and Internal Medicine business units, as well as Expanded Access initiatives. Based in New York, Michael joined Pfizer in 2016 after 10 years practicing in the litigation department at Kaye Scholer, LLP.
JONATHAN WALLAND is Senior Corporate Counsel at Pfizer where he provides strategic legal advice to help physicians and patients bring cutting-edge new drugs and vaccines to market. Drawing on his experience in health care, pharmaceuticals, and compliance, he works on innovative research transactions in oncology, vaccines, and rare diseases. These collaborations vary from traditional pharma research to exciting data sharing initiatives and licensing transactions. Previously he was Associate General Counsel at the Memorial Sloan-Kettering Cancer Center in New York and Legal Counsel at Inotek Pharmaceuticals Corporation (NASDAQ: ITEK). Jonathan holds a BCL and LLB from McGill University in Montreal, Canada and is a member of the New York Bar. Jonathan studied business at the Wharton School of the University of Pennsylvania and earned an MBA from INSEAD in Fontainebleau, France.Get Access
$99
- +$100 for nonmembers
Virtual Learning FAQ
Related Content
